Panacea to start commercial production of Sputnik V from summer – Times of India

[ad_1]

The first batch produced at Panacea Biotec’s amenities at Baddi might be shipped to Russia’s Gamaleya Center for “quality control”. (File picture)

MUMBAI: Panacea Biotec and Russia’s sovereign wealth fund, Russian Direct Investment Fund (RDIF) introduced the start of production of the Sputnik V vaccine, with commercial manufacture kick-beginning in summer. Under a tie-up, RDIF and Panacea have agreed to produce 100 million doses per yr of the vaccine.
The first batch produced at Panacea Biotec’s amenities at Baddi might be shipped to Russia’s Gamaleya Center for “quality control”, an organization assertion mentioned. The amenities adjust to GMP (good manufacturing practices) and are prequalified by WHO, it provides.
Sputnik V was registered in India below the emergency use authorization process on April 12, and vaccination with the Russian vaccine began on May 14. The preliminary roll-out has been accomplished with the doses imported from Russia by RDIF’s accomplice, Dr Reddy’s, with the jab priced round Rs 995 per dose.
Rajesh Jain, managing director of Panacea Biotec, mentioned “This marks a major step as we provoke production of Sputnik V.”
According to Kirill Dmitriev, CEO of RDIF: “Production of Sputnik V supports efforts of India’s authorities to leave behind the acute phase of coronavirus as soon as possible while the vaccine will also be exported at a later stage to help prevent the spread of the virus in other countries around the world.”
Efficacy of Sputnik V is 97.6% based on the analysis of data on coronavirus infection rate among those in Russia vaccinated with both doses of Sputnik V from December 2020 to March 2021, the company claims.

FacebookTwitterLinkedinEMail



[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *